Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial

Lin, Yan; Liang, Huan-Wei; Liu, Yang; Pan, Xin-Bin

doi:10.3389/fimmu.2023.1264912

Cited by 3 publications

(1 citation statement)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, a better prognosis was observed in the ypT+N0 group than in the ypT0N+ and ypT+N+ groups with regard to non-pathological complete remission ( 17 ). Additionally, the CheckMate 577 trial subgroup analysis did not show a statistically significant benefit of adjuvant nivolumab for the ypN0 group ( 18 ). However, to the best of our knowledge, no analysis for estimating its prognosis after NAC with DCF followed by curative surgery has been done on the four pathological types of esophageal cancer, ypT0N0, ypT+N0, ypT0N+, and ypT+N+.…”

Section: Introductionmentioning

confidence: 99%

Equivalent prognosis with no lymph node metastasis to pathological complete remission in patients with localized advanced esophageal cancer after neoadjuvant triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative surgery: a single-center retrospective cohort study

Chinen,

Yamaguchi,

Ohzawa

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

Background Adjuvant nivolumab therapy has become the standard therapy for patients with localized advanced esophageal cancer with non-pathological complete response after neoadjuvant chemoradiotherapy followed by curative surgery. However, the necessity of this therapy for patients after neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen followed by surgery is unclear, and the prognosis of grouping based on the presence or absence of pathological tumor and lymph node findings has not been analyzed. Therefore, our study aimed to address these questions. Methods This retrospective cohort study included patients with cT1N1–3M0 and cT2–3N0–3M0 esophageal cancer according to the Japanese Classification of Esophageal Cancer, 11th edition, who received NAC with DCF followed by curative surgery between 2008 and 2020 at Jichi Medical University Hospital. We divided patients with ypT0−3N0−3M0 into four histological groups, namely ypT0N0, ypT+N0, ypT0N+, and ypT+N+, and we evaluated overall survival as the primary outcome and the prognostic relationship of lymph node metastasis as the secondary outcome. Results A total of 101 patients were included in this study. Kaplan-Meier analysis showed that the curves of the ypT0N0 and ypT+N0 groups were almost identical, while they differed from the other two groups. The hazard ratio of ypN+ was 4.44 (95% confidence interval: 2.03–9.71; P<0.001). Conclusions The prognosis of the ypT+N0 group after NAC with DCF followed by surgery was similar to that of pathological complete remission. Grouping patients according to pathological lymph node status is a reasonable predictor of prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Equivalent prognosis with no lymph node metastasis to pathological complete remission in patients with localized advanced esophageal cancer after neoadjuvant triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative surgery: a single-center retrospective cohort study

Chinen,

Yamaguchi,

Ohzawa

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

show abstract

Präoperative Radiochemo- versus Chemotherapie des ösophagogastralen Übergangs

Rieken,

Guhlich,

Leu

et al. 2024

Onkologie

View full text Add to dashboard Cite

Therapeutic efficacy of immunotherapy for gastric cancer metastasis

Xie,

Qian,

Zhao

et al. 2024

World J Gastrointest Surg

View full text Add to dashboard Cite

Gastric cancer (GC) metastasis is the main cause of poor prognosis for GC patients. In recent years, breakthroughs in immunotherapy have been made in the treatment of many kinds of cancers, providing new hope for patients with GC metastasis. This paper reviews the mechanism of immunotherapy in GC metastasis and its clinical application, and discusses and compares the research and efficacy of immunotherapy in patients with liver metastasis, lung metastasis, peritoneal metastasis and lymph node metastasis of GC. This study explores the challenges and future development directions of immunotherapy, and provides a theoretical basis and clinical guidance for the precise treatment of patients with GC metastasis.

show abstract

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial

Cited by 3 publications

References 87 publications

Equivalent prognosis with no lymph node metastasis to pathological complete remission in patients with localized advanced esophageal cancer after neoadjuvant triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative surgery: a single-center retrospective cohort study

Equivalent prognosis with no lymph node metastasis to pathological complete remission in patients with localized advanced esophageal cancer after neoadjuvant triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative surgery: a single-center retrospective cohort study

Präoperative Radiochemo- versus Chemotherapie des ösophagogastralen Übergangs

Therapeutic efficacy of immunotherapy for gastric cancer metastasis

Contact Info

Product

Resources

About